INTERVENTION 1:	Intervention	0
Arm 1: Paclitaxel + Trastuzumab Then A C	Intervention	1
paclitaxel	CHEBI:45863	7-17
4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Following paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)	Intervention	2
paclitaxel	CHEBI:45863	12-22
paclitaxel	CHEBI:45863	102-112
paclitaxel	CHEBI:45863	199-209
surgery	OAE:0000067	273-280
year	UO:0000036	359-363
neratinib	CHEBI:61397	428-437
Paclitaxel	Intervention	3
paclitaxel	CHEBI:45863	0-10
Trastuzumab	Intervention	4
Doxorubicin	Intervention	5
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide	Intervention	6
cyclophosphamide	CHEBI:4026	0-16
INTERVENTION 2:	Intervention	7
Arm 2: Paclitaxel + Neratinib Then A C	Intervention	8
paclitaxel	CHEBI:45863	7-17
neratinib	CHEBI:61397	20-29
4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)	Intervention	9
paclitaxel	CHEBI:45863	12-22
paclitaxel	CHEBI:45863	129-139
paclitaxel	CHEBI:45863	192-202
paclitaxel	CHEBI:45863	214-224
neratinib	CHEBI:61397	72-81
neratinib	CHEBI:61397	225-234
neratinib	CHEBI:61397	449-458
day	UO:0000033	35-38
day	UO:0000033	61-64
day	UO:0000033	120-123
day	UO:0000033	163-166
day	UO:0000033	265-268
surgery	OAE:0000067	294-301
year	UO:0000036	380-384
Paclitaxel	Intervention	10
paclitaxel	CHEBI:45863	0-10
Neratinib	Intervention	11
neratinib	CHEBI:61397	0-9
Doxorubicin	Intervention	12
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide	Intervention	13
cyclophosphamide	CHEBI:4026	0-16
Inclusion Criteria:	Eligibility	0
Patients should have a life expectancy of at least 10 years, excluding their diagnosis of breast cancer.	Eligibility	1
breast cancer	DOID:1612	90-103
Submission of a block from the diagnostic biopsy sample and from the surgical sample, if gross residual disease greater than or equal to 1.0 cm was removed at the time of surgery, is required for all patients	Eligibility	2
disease	DOID:4,OGMS:0000031	104-111
time	PATO:0000165	163-167
surgery	OAE:0000067	171-178
Patients of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy and for at least 6 months after the last dose of study therapy.	Eligibility	3
The Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1.	Eligibility	4
group	CHEBI:24433	33-38
Patients must have the ability to swallow oral medication.	Eligibility	5
The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or by limited incisional biopsy.	Eligibility	6
adenocarcinoma	DOID:299	26-40
breast	UBERON:0000310	48-54
Patients must have ER analysis performed on the primary tumor prior to randomization. If ER analysis is negative, then progesterone receptor (PgR) analysis must also be performed. (Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors.)	Eligibility	7
progesterone	CHEBI:17026	119-131
receptor	BAO:0000281	132-140
receptor	BAO:0000281	223-231
receptor	BAO:0000281	252-260
hormone	CHEBI:24621	215-222
hormone	CHEBI:24621	244-251
Breast cancer must be determined to be HER2-positive prior to randomization. Assays using FISH or CISH require gene amplification. Assays using IHC require a strongly positive (3+) staining score.	Eligibility	8
breast cancer	DOID:1612	0-13
gene	BAO:0000582	111-115
Clinical staging, based on the assessment by physical exam, must be American Joint Committee on Cancer (AJCC) stage IIB, IIIA, IIIB, or IIIC: cT2 and cN1; cT3 and cN0 or cN1; Any cT and cN2 or cN3; or cT4	Eligibility	9
cancer	DOID:162	96-102
ct	BAO:0002125	142-144
ct	BAO:0002125	155-157
ct	BAO:0002125	179-181
ct	BAO:0002125	201-203
The patient must have a mass in the breast or axilla measuring greater than or equal to 2.0 cm by physical exam, unless the patient has inflammatory breast cancer, in which case measurable disease by physical exam is not required.	Eligibility	10
patient	HADO:0000008,OAE:0001817	4-11
patient	HADO:0000008,OAE:0001817	124-131
breast	UBERON:0000310	36-42
breast	UBERON:0000310	149-155
breast cancer	DOID:1612	149-162
disease	DOID:4,OGMS:0000031	189-196
At the time of randomization, blood counts performed within 4 weeks prior to randomization must meet the following criteria: absolute neutrophil count (ANC) must be greater than or equal to 1200/mm3; Platelet count must be greater than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 10 g/dL	Eligibility	11
time	PATO:0000165	7-11
blood	UBERON:0000178	30-35
platelet count	CMO:0000029	200-214
hemoglobin	CHEBI:35143	261-271
The following criteria for evidence of adequate hepatic function performed within 4 weeks prior to randomization must be met: total bilirubin must be less than or equal to upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation greater than ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab; and aspartate aminotransferase (AST) and ALT must be less than or equal to 1.5 x ULN for the lab.	Eligibility	12
function	BAO:0003117,BFO:0000034	56-64
patient	HADO:0000008,OAE:0001817	223-230
x	LABO:0000148	281-282
x	LABO:0000148	432-433
x	LABO:0000148	530-531
disease	DOID:4,OGMS:0000031	304-311
syndrome	DOID:225	323-331
phosphatase	GO:0016791,BAO:0000295	386-397
aspartate	CHEBI:29995	455-464
Patients with alkaline phosphatase greater than ULN but less than or equal to 2.5 x ULN are eligible for inclusion in the study if liver imaging (CT, MRI, PET, or PET-CT scan) performed within 4 weeks prior to randomization does not demonstrate metastatic disease and the requirements for adequate hepatic function are met.	Eligibility	13
phosphatase	GO:0016791,BAO:0000295	23-34
x	LABO:0000148	82-83
liver	UBERON:0002107	131-136
ct	BAO:0002125	146-148
ct	BAO:0002125	167-169
ct	BAO:0002125	309-311
disease	DOID:4,OGMS:0000031	256-263
function	BAO:0003117,BFO:0000034	306-314
Patients with either unexplained skeletal pain or alkaline phosphatase that is greater than ULN but less than or equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 4 weeks prior to randomization does not demonstrate metastatic disease. Patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are determined to be benign by x-ray, MRI, or biopsy.	Eligibility	14
pain	HP:0012531	42-46
phosphatase	GO:0016791,BAO:0000295	59-70
x	LABO:0000148	24-25
x	LABO:0000148	126-127
x	LABO:0000148	428-429
disease	DOID:4,OGMS:0000031	293-300
Serum creatinine performed within 4 weeks prior to randomization must be less than or equal to 1.5 x ULN for the lab.	Eligibility	15
creatinine	CHEBI:16737	6-16
x	LABO:0000148	99-100
The left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or multiple gated acquisition(MUGA) scan performed within 90 days prior to randomization must be greater than or equal to 50% regardless of the facility's LLN.	Eligibility	16
left	HP:0012835	4-8
ejection fraction	CMO:0000180	21-38
Exclusion Criteria:	Eligibility	17
fine-needle aspiration (FNA) alone to diagnose the primary breast cancer.	Eligibility	18
aspiration	HP:0002835	12-22
breast cancer	DOID:1612	59-72
Excisional biopsy or lumpectomy performed prior to randomization.	Eligibility	19
Surgical axillary staging procedure prior to randomization. (Procedures that are permitted prior to study entry include: 1) FNA or core biopsy of an axillary node for any patient, and 2) although not recommended, a pre-neoadjuvant therapy SN biopsy for patients with clinically negative axillary nodes.)	Eligibility	20
patient	HADO:0000008,OAE:0001817	171-178
patient	HADO:0000008,OAE:0001817	253-260
Definitive clinical or radiologic evidence of metastatic disease. (Note: Chest imaging [mandatory for all patients] and other imaging [if required] must have been performed within 90 days prior to randomization.)	Eligibility	21
disease	DOID:4,OGMS:0000031	57-64
chest	UBERON:0001443	73-78
History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral ductal carcinoma in situ (DCIS) treated with radiation therapy (RT). (Patients with a history of LCIS are eligible.)	Eligibility	22
history	BFO:0000182	0-7
history	BFO:0000182	171-178
breast cancer	DOID:1612	32-45
ductal carcinoma in situ	HP:0030075,DOID:0060074	85-109
Contralateral invasive breast cancer at any time. (Patients with contralateral DCIS or lobular carcinoma in situ (LCIS) are eligible.)	Eligibility	23
breast cancer	DOID:1612	23-36
time	PATO:0000165	44-48
lobular carcinoma in situ	HP:0030076,DOID:3010	87-112
History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization.	Eligibility	24
history	BFO:0000182	0-7
Known metastatic disease from any malignancy (solid tumor or hematologic).	Eligibility	25
disease	DOID:4,OGMS:0000031	17-24
Previous therapy with anthracyclines, taxanes, cyclophosphamide, trastuzumab, or neratinib for any malignancy.	Eligibility	26
cyclophosphamide	CHEBI:4026	47-63
neratinib	CHEBI:61397	81-90
Treatment including RT, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to randomization.	Eligibility	27
breast cancer	DOID:1612	104-117
Continued endocrine therapy such as raloxifene or tamoxifen (or other SERM) or an aromatase inhibitor. (Patients are eligible if these medications are discontinued prior to randomization.)	Eligibility	28
raloxifene	CHEBI:8772	36-46
tamoxifen	CHEBI:41774	50-59
inhibitor	CHEBI:35222	92-101
Any continued sex hormonal therapy, e.g., birth control pills and ovarian hormone replacement therapy. Patients are eligible if these medications are discontinued prior to randomization.	Eligibility	29
hormone	CHEBI:24621	74-81
Active hepatitis B or hepatitis C with abnormal liver function tests.	Eligibility	30
active	PATO:0002354	0-6
hepatitis b	DOID:2043	7-18
hepatitis c	DOID:1883	22-33
liver	UBERON:0002107	48-53
function	BAO:0003117,BFO:0000034	54-62
Intrinsic lung disease resulting in dyspnea.	Eligibility	31
lung disease	DOID:850	10-22
dyspnea	HP:0002094	36-43
Active infection or chronic infection requiring chronic suppressive antibiotics.	Eligibility	32
active	PATO:0002354	0-6
chronic infection	HP:0031035	20-37
chronic	HP:0011010	20-27
chronic	HP:0011010	48-55
Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small bowel, or other disease or condition significantly affecting gastrointestinal function.	Eligibility	33
malabsorption	HP:0002024	0-13
syndrome	DOID:225	14-22
ulcerative colitis	HP:0100279,DOID:8577	24-42
inflammatory bowel disease	DOID:0050589	44-70
stomach	UBERON:0000945	89-96
disease	DOID:4,OGMS:0000031	63-70
disease	DOID:4,OGMS:0000031	122-129
condition	PDRO:0000129	133-142
function	BAO:0003117,BFO:0000034	184-192
Persistent greater than or equal to grade 2 diarrhea regardless of etiology.	Eligibility	34
diarrhea	HP:0002014,DOID:13250	44-52
Sensory or motor neuropathy greater than or equal to grade 2, as defined by the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0.	Eligibility	35
neuropathy	DOID:870	17-27
Conditions that would prohibit intermittent administration of corticosteroids for paclitaxel premedication.	Eligibility	36
paclitaxel	CHEBI:45863	82-92
Chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids).	Eligibility	37
chronic	HP:0011010	0-7
Uncontrolled hypertension defined as a systolic BP greater than 150 mmHg or diastolic BP greater than 90 mmHg, with or without anti-hypertensive medications. (Patients with hypertension that is well-controlled on medication are eligible.)	Eligibility	38
hypertension	HP:0000822,DOID:10763	13-25
hypertension	HP:0000822,DOID:10763	173-185
Cardiac disease (history of and/or active disease) that would preclude the use of any of the drugs included in the treatment regimen. This includes but is not confined to: Active cardiac disease: symptomatic angina pectoris within the past 180 days that required the initiation of or increase in anti-anginal medication or other intervention; ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; valvular disease with documented compromise in cardiac function; and symptomatic pericarditis. History of cardiac disease: myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function; history of documented congestive heart failure (CHF); and documented cardiomyopathy.	Eligibility	39
disease	DOID:4,OGMS:0000031	8-15
disease	DOID:4,OGMS:0000031	42-49
disease	DOID:4,OGMS:0000031	187-194
disease	DOID:4,OGMS:0000031	572-579
disease	DOID:4,OGMS:0000031	677-684
history	BFO:0000182	17-24
history	BFO:0000182	658-665
history	BFO:0000182	819-826
active	PATO:0002354	35-41
active	PATO:0002354	172-178
angina pectoris	HP:0001681	208-223
increase	BAO:0001251	284-292
function	BAO:0003117,BFO:0000034	618-626
function	BAO:0003117,BFO:0000034	809-817
pericarditis	HP:0001701,DOID:1787	644-656
myocardial infarction	HP:0001658,DOID:5844	686-707
congestive heart failure	HP:0001635,DOID:6000	841-865
cardiomyopathy	HP:0001638,DOID:0050700	888-902
Other nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up.	Eligibility	40
disease	DOID:4,OGMS:0000031	28-35
patient	HADO:0000008,OAE:0001817	60-67
Pregnancy or lactation at the time of randomization.	Eligibility	41
lactation	GO:0007595	13-22
time	PATO:0000165	30-34
The investigator should assess the patient to determine if she has any psychiatric or addictive disorder or other condition that, in the opinion of the investigator, would preclude her from meeting the study requirements.	Eligibility	42
patient	HADO:0000008,OAE:0001817	35-42
disorder	OGMS:0000045	96-104
condition	PDRO:0000129	114-123
Use of any investigational agent within 4 weeks prior to randomization.	Eligibility	43
Outcome Measurement:	Results	0
Pathologic Complete Response in Breast and Axillary Lymph Nodes.	Results	1
breast	UBERON:0000310	32-38
lymph	UBERON:0002391	52-57
Number of participants with no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes after neoadjuvant chemotherapy	Results	2
breast	UBERON:0000310	91-97
Time frame: At time of surgery, approximately 7 months	Results	3
time	PATO:0000165	0-4
time	PATO:0000165	15-19
surgery	OAE:0000067	23-30
Results 1:	Results	4
Arm/Group Title: Arm 1: Paclitaxel + Trastuzumab Then A C	Results	5
paclitaxel	CHEBI:45863	24-34
Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Following paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)	Results	6
paclitaxel	CHEBI:45863	35-45
paclitaxel	CHEBI:45863	125-135
paclitaxel	CHEBI:45863	222-232
surgery	OAE:0000067	296-303
year	UO:0000036	382-386
neratinib	CHEBI:61397	451-460
Paclitaxel	Results	7
paclitaxel	CHEBI:45863	0-10
Trastuzumab	Results	8
Doxorubicin	Results	9
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide	Results	10
cyclophosphamide	CHEBI:4026	0-16
Overall Number of Participants Analyzed: 42	Results	11
Measure Type: Count of Participants	Results	12
Unit of Measure: Participants  16  38.1%	Results	13
Results 2:	Results	14
Arm/Group Title: Arm 2: Paclitaxel + Neratinib Then A C	Results	15
paclitaxel	CHEBI:45863	24-34
neratinib	CHEBI:61397	37-46
Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)	Results	16
paclitaxel	CHEBI:45863	35-45
paclitaxel	CHEBI:45863	152-162
paclitaxel	CHEBI:45863	215-225
paclitaxel	CHEBI:45863	237-247
neratinib	CHEBI:61397	95-104
neratinib	CHEBI:61397	248-257
neratinib	CHEBI:61397	472-481
day	UO:0000033	58-61
day	UO:0000033	84-87
day	UO:0000033	143-146
day	UO:0000033	186-189
day	UO:0000033	288-291
surgery	OAE:0000067	317-324
year	UO:0000036	403-407
Paclitaxel	Results	17
paclitaxel	CHEBI:45863	0-10
Neratinib	Results	18
neratinib	CHEBI:61397	0-9
Doxorubicin	Results	19
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide	Results	20
cyclophosphamide	CHEBI:4026	0-16
Overall Number of Participants Analyzed: 42	Results	21
Measure Type: Count of Participants	Results	22
Unit of Measure: Participants  14  33.3%	Results	23
Adverse Events 1:	Adverse Events	0
Total: 7/42 (16.67%)	Adverse Events	1
Febrile neutropenia 1/42 (2.38%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Left venrticular dysfunction 1/42 (2.38%)	Adverse Events	3
left	HP:0012835	0-4
Cardiac valve disease 1/42 (2.38%)	Adverse Events	4
valve	UBERON:0003978	8-13
disease	DOID:4,OGMS:0000031	14-21
Diarrhoea 0/42 (0.00%)	Adverse Events	5
Abdominal pain 1/42 (2.38%)	Adverse Events	6
abdominal pain	HP:0002027	0-14
Colitis 0/42 (0.00%)	Adverse Events	7
colitis	HP:0002583,DOID:0060180	0-7
Nausea 0/42 (0.00%)	Adverse Events	8
nausea	HP:0002018	0-6
Vomiting 0/42 (0.00%)	Adverse Events	9
vomiting	HP:0002013	0-8
Pyrexia 0/42 (0.00%)	Adverse Events	10
Influenza like illness 1/42 (2.38%)	Adverse Events	11
influenza	DOID:8469	0-9
Oedema peripheral 1/42 (2.38%)	Adverse Events	12
peripheral	HP:0030646	7-17
Fatigue 0/42 (0.00%)	Adverse Events	13
fatigue	HP:0012378	0-7
Adverse Events 2:	Adverse Events	14
Total: 7/42 (16.67%)	Adverse Events	15
Febrile neutropenia 0/42 (0.00%)	Adverse Events	16
neutropenia	HP:0001875,DOID:1227	8-19
Left venrticular dysfunction 1/42 (2.38%)	Adverse Events	17
left	HP:0012835	0-4
Cardiac valve disease 0/42 (0.00%)	Adverse Events	18
valve	UBERON:0003978	8-13
disease	DOID:4,OGMS:0000031	14-21
Diarrhoea 0/42 (0.00%)	Adverse Events	19
Abdominal pain 0/42 (0.00%)	Adverse Events	20
abdominal pain	HP:0002027	0-14
Colitis 0/42 (0.00%)	Adverse Events	21
colitis	HP:0002583,DOID:0060180	0-7
Nausea 0/42 (0.00%)	Adverse Events	22
nausea	HP:0002018	0-6
Vomiting 0/42 (0.00%)	Adverse Events	23
vomiting	HP:0002013	0-8
Pyrexia 2/42 (4.76%)	Adverse Events	24
Influenza like illness 0/42 (0.00%)	Adverse Events	25
influenza	DOID:8469	0-9
Oedema peripheral 0/42 (0.00%)	Adverse Events	26
peripheral	HP:0030646	7-17
Fatigue 0/42 (0.00%)	Adverse Events	27
fatigue	HP:0012378	0-7
